New hope for Hard-to-Treat blood cancer: drug combo trial launches
NCT ID NCT07570017
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This early-phase trial tests a new drug, rocbrutinib, combined with standard chemotherapy (R-GemOx) in 42 adults with a specific type of diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to find the safest dose and check for side effects. Researchers will also look at whether the combination helps shrink tumors and how long that effect lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
Conditions
Explore the condition pages connected to this study.